Aiolos Bio: GSK completes acquisition of Aiolos Bio
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
Read full article »
Aiolos Bio is a Massachusetts-based clinical-stage biopharmaceutical company that researches and develops novel therapeutics for respiratory and inflammatory diseases.
Read more